Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Actavis Inc    

SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Watson Says Received Favorable Ruling Over Generic Sanctura XR

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/04/2012 | 12:19am CEST

Watson Pharmaceuticals Inc. (>> Watson Pharmaceuticals, Inc.) said it received a favorable court ruling over a patent dispute with Allergan Inc. (AGN) and its business partners regarding Watson's plans for a generic version of an overactive bladder medication.

Allergan and its partners in 2009 sued Watson and its business partners, alleging infringement of patents related to Allergan's Sanctura XR drug.

Watson said Tuesday a U.S. District Court in Delaware found several Sanctura XR patents invalid, benefiting Watson and allowing it to potentially move forward with its abbreviated new drug application for generic version of the drug, which is pending with the Food and Drug Administration.

An Allergan representative wasn't immediately available for comment.

Watson has seen strong sales of its generics as health-care companies and consumers try to reduce spending on health-related products and services. Watson is trying to expand its brand-name drug business, though it recently hit a regulatory setback with a proposed new drug to prevent premature births.

The company benefited from its introduction of authorized generic versions of Johnson & Johnson's (JNJ) Concerta treatment for attention-deficit/hyperactivity disorder in May, as well as Pfizer's (PFE) Lipitor cholesterol-lowering drug in November.

Watson in February said its fourth-quarter profit surged as the introduction of generic Lipitor and other products boosted sales.

Watson's shares closed Tuesday at $66.96 and were down 6 cents after hours. Allergan's shares closed at $95.27 and were off 10 cents after hours.

-By Ben Fox Rubin, Dow Jones Newswires; 212-416-3108; ben.rubin@dowjones.com

Stocks mentioned in the article : Watson Pharmaceuticals, Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ACTAVIS INC
07/21DJAmgen and Allergan Study Finds Biosimilar Comparable to Herceptin
07/20DJJOHNSON & JOHNSON : Jury Acquits Former Johnson & Johnson Unit Executives of Fel..
07/20DJJOHNSON & JOHNSON : Jury Acquits Former Johnson & Johnson Unit Executives of Fel..
07/19 SoftBank bid for ARM catches some hedge funds off guard
07/18DJTEVA PHARMACEUTICAL : Sells $15 Billion of Bonds
07/18DJTEVA PHARMACEUTICAL : Finalizes Bond Sale -- Update
07/18DJTEVA PHARMACEUTICAL : Finalizes Bond Sale
07/18DJTeva Sells $15 Billion of Bonds
07/13DJTEVA PHARMACEUTICAL : Allergan Tweak Acquisition Agreement
07/13DJTEVA PHARMACEUTICAL : Allergan Tweak Acquisition Agreement
More news
Sector news : Pharmaceuticals - NEC
07:11pDJPFIZER : Cleared to Buy Nanotech Drug Firm Bind Therapeutics
07:02pDJVECTURA : Initiates Legal Proceedings Against GSK
05:01pDJGLAXOSMITHKLINE : Helped and Hurt by Sterling's Post-Brexit Fall
03:02pDJBAYER : Reports Higher Second-Quarter Profit, Raises Guidance -- 2nd Update
02:33pDJGLAXOSMITHKLINE : Glaxo Swings to Loss on Write-Down But Core Earnings, Revenue ..
More sector news : Pharmaceuticals - NEC
Advertisement
Financials ($)
Sales 2016 16 714 M
EBIT 2016 7 814 M
Net income 2016 -193 M
Debt 2016 14 520 M
Yield 2016 -
P/E ratio 2016 602,35
P/E ratio 2017 96,24
EV / Sales 2016 6,76x
EV / Sales 2017 5,90x
Capitalization 98 474 M
More Financials
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 293 $
Spread / Average Target 18%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Brenton L. Saunders President, Chief Executive Officer & Director
Paul M. Bisaro Executive Chairman
Robert A. Stewart Chief Operating Officer
Maria Teresa Hilado Chief Financial Officer
C. David Nicholson Chief Research & Development Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ACTAVIS INC98 474
JOHNSON & JOHNSON21.84%344 243
PFIZER INC.14.10%223 368
NOVARTIS AG-5.30%219 971
ROCHE HOLDING LTD.-9.99%218 902
MERCK & CO., INC.10.49%161 542
More Results